UY24774A1 - Procedimiento para piridinas sustituidas - Google Patents
Procedimiento para piridinas sustituidasInfo
- Publication number
- UY24774A1 UY24774A1 UY24774A UY24774A UY24774A1 UY 24774 A1 UY24774 A1 UY 24774A1 UY 24774 A UY24774 A UY 24774A UY 24774 A UY24774 A UY 24774A UY 24774 A1 UY24774 A1 UY 24774A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compound
- procedure
- useful
- substituted pyridines
- acetylaminopyridin
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940125710 antiobesity agent Drugs 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- MNRSVDHPRAZFQV-NRFANRHFSA-N tert-butyl n-[(2r)-2-(6-acetamidopyridin-3-yl)-2-hydroxyethyl]-n-[2-[4-[2-(methylamino)-2-oxoethyl]phenoxy]ethyl]carbamate Chemical compound C1=CC(CC(=O)NC)=CC=C1OCCN(C(=O)OC(C)(C)C)C[C@H](O)C1=CC=C(NC(C)=O)N=C1 MNRSVDHPRAZFQV-NRFANRHFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3088096P | 1996-11-14 | 1996-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY24774A1 true UY24774A1 (es) | 1998-05-05 |
Family
ID=21856496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY24774A UY24774A1 (es) | 1996-11-14 | 1997-11-12 | Procedimiento para piridinas sustituidas |
Country Status (32)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010042518A (ko) * | 1998-04-08 | 2001-05-25 | 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 | 신규 제초제 |
| US6090942A (en) * | 1998-10-15 | 2000-07-18 | Pfizer Inc. | Process and intermediates for a β3 -adrenergic receptor agonist |
| KR20010102198A (ko) * | 1999-02-16 | 2001-11-15 | 후루타 타케시 | 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법 |
| US6455734B1 (en) | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| ATE280167T1 (de) * | 1999-07-23 | 2004-11-15 | Pfizer Prod Inc | Zwischenprodukte und ein verfahren zur herstellung von beta3-adrenergischer rezeptor- agoniste |
| US20040265991A1 (en) * | 2001-10-17 | 2004-12-30 | Naoaki Taoka | Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives |
| BR0307996A (pt) | 2002-02-27 | 2004-12-07 | Pfizer Prod Inc | Processos e intermediários úteis na preparação de receptores de agonistas beta3-adrenérgicos |
| WO2003072573A1 (en) * | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| AU2004235923B2 (en) | 2003-05-09 | 2008-01-24 | F. Hoffmann-La Roche Ag | Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358455A (en) | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
| US5019578A (en) | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| NZ265692A (en) | 1993-06-14 | 1997-02-24 | Pfizer | Indole- and benzofuran- containing hydroxyamines and analogs; pharmaceutical compositions |
| IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| JPH11504648A (ja) * | 1995-05-10 | 1999-04-27 | ファイザー・インコーポレーテッド | β−アドレナリン作動性アゴニスト |
| MX9708621A (es) | 1995-05-10 | 1998-02-28 | Pfizer | AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS. |
-
1997
- 1997-11-03 EP EP97945047A patent/EP0938476B1/en not_active Expired - Lifetime
- 1997-11-03 AU AU46346/97A patent/AU4634697A/en not_active Abandoned
- 1997-11-03 KR KR1019990704312A patent/KR20000053314A/ko active IP Right Grant
- 1997-11-03 US US09/297,694 patent/US6291489B1/en not_active Expired - Fee Related
- 1997-11-03 DE DE69735433T patent/DE69735433D1/de not_active Expired - Lifetime
- 1997-11-03 BR BR9712951-8A patent/BR9712951A/pt not_active Application Discontinuation
- 1997-11-03 TR TR1999/01063T patent/TR199901063T2/xx unknown
- 1997-11-03 WO PCT/IB1997/001367 patent/WO1998021184A1/en active IP Right Grant
- 1997-11-03 AT AT97945047T patent/ATE319687T1/de not_active IP Right Cessation
- 1997-11-03 CN CN97199663A patent/CN1237160A/zh active Pending
- 1997-11-03 EA EA199900375A patent/EA199900375A1/ru unknown
- 1997-11-03 YU YU22099A patent/YU22099A/sh unknown
- 1997-11-03 IL IL12968897A patent/IL129688A0/xx unknown
- 1997-11-03 JP JP52233298A patent/JP3510635B2/ja not_active Expired - Fee Related
- 1997-11-03 CA CA002270386A patent/CA2270386C/en not_active Expired - Fee Related
- 1997-11-11 PE PE1997001004A patent/PE10299A1/es not_active Application Discontinuation
- 1997-11-11 GT GT199700118A patent/GT199700118A/es unknown
- 1997-11-11 MA MA24864A patent/MA24401A1/fr unknown
- 1997-11-12 AR ARP970105279A patent/AR010584A1/es not_active Application Discontinuation
- 1997-11-12 MY MYPI97005396A patent/MY132507A/en unknown
- 1997-11-12 UY UY24774A patent/UY24774A1/es unknown
- 1997-11-12 ZA ZA9710186A patent/ZA9710186B/xx unknown
- 1997-11-12 PA PA19978441401A patent/PA8441401A1/es unknown
- 1997-11-12 TN TNTNSN97172A patent/TNSN97172A1/fr unknown
- 1997-11-13 AP APAP/P/1997/001147A patent/AP805A/en active
- 1997-11-13 ID IDP973662A patent/ID18898A/id unknown
- 1997-11-13 HR HR60/030,880A patent/HRP970612A2/hr not_active Application Discontinuation
- 1997-11-13 CO CO97066763A patent/CO4930261A1/es unknown
-
1999
- 1999-04-16 IS IS5029A patent/IS5029A/is unknown
- 1999-05-07 OA OA9900096A patent/OA11044A/en unknown
- 1999-05-11 BG BG103393A patent/BG103393A/xx unknown
- 1999-05-12 NO NO992296A patent/NO992296L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY24774A1 (es) | Procedimiento para piridinas sustituidas | |
| AR003955A1 (es) | Derivados de n-(indol-2-carbonil)-glicinamidas, procedimiento para su obtencion y composiciones que los contienen. | |
| ES2124062T3 (es) | Derivados de nucleosido fosforotioato, sintesis y uso de los mismos. | |
| ES2213732T3 (es) | Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos. | |
| BR9406362A (pt) | Composto,processo para a preparação do mesmo e composição anti-nuclear | |
| ES2187983T3 (es) | Derivados 1,2,3,4-tetrahidronaftaleno sustituidos. | |
| ES2170403T3 (es) | Derivados de n-bencil-piperidina y tetrahidro-piridina. | |
| PE20001084A1 (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
| ES2157683T3 (es) | 4-hidroxiindoles cationicos y su utilizacion para el teñido por oxidacion de las fibras queratinicas. | |
| ES2179353T3 (es) | Antagonistas muscarinicos. | |
| AR015449A1 (es) | Derivados piperidil- o peperazinil-dihidro sustituidos-2h-1-benzopirano composicion farmaceutica que los contiene, su uso para la elaboracion de unmedicamento, procedimiento para su preparacion y compuesto intermediario para su exclusivo uso en dicho procedimiento | |
| KR910016745A (ko) | 3-아릴카르보닐-1-아미노알킬-1h-인돌류,이를 함유하는 항녹내장 조성물 및 이의 제조 방법 | |
| ATE423555T1 (de) | Verwendung von beta-3-adrenergen-rezeptoren agonisten in der behandlung von dysurie | |
| ES2051011T3 (es) | Procedimiento de deslavado heterogeneo de articulos a base de algodon teñido. | |
| TW356468B (en) | Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same | |
| MX168469B (es) | Procedimiento para la preparacion de derivados aminoalcoholes acilados | |
| AR001813A1 (es) | Derivados de cromona procedimiento para prepararlos y las composiciones farmacéutica que los contienen | |
| ES2141445T3 (es) | Derivados triciclicos, su preparacion y su aplicacion a la preparacion de la colchicina y la tiocolchicina opticamente activos o racemicos y analogos o derivados o productos intermedios. | |
| ES2183328T3 (es) | Derivados de ciclopentenona. | |
| FI962261A0 (fi) | N-bis- tai N-tris-((1,2-dikarboksyyli-etoksi)-etyyN-bis- tai N-tris-((1,2-dikarboksyyli-etoksi)-etyyli)amiinijohdannaiset, niiden valmistus ja käyttö li)amiinijohdannaiset, niiden valmistus ja käyttö | |
| BR9811348A (pt) | Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas. | |
| DE19847276A1 (de) | Färbemittel mit Enzymen | |
| AR004015A1 (es) | Procedimiento para preparar compuestos de quinolina o sales farmaceuticamente aceptables de los mismos, y compuestos intermediarios | |
| BR9610175A (pt) | Composto processo de preparação do composto composição farmacêutica e utilização do composto | |
| ES2193568T3 (es) | Procedimiento de preparacion de lactamas n-derivadas enriquecidas enantiomericamente. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20001222 |